{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,17]],"date-time":"2026-10-17T03:06:52Z","timestamp":1792206412815,"version":"4.4.0"},"reference-count":24,"publisher":"American Society of Hematology","issue":"25","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2024,6,20]]},"abstract":"<jats:sec>\n                    <jats:title>Abstract<\/jats:title>\n                    <jats:p>Previous studies have demonstrated that &amp;gt;38% of patients with immune-mediated thrombotic thrombocytopenic purpura in remission with activity &amp;gt;50% had an open ADAMTS13 (a disintegrin and metalloproteinase with thrombospondin type 1 motif, member 13) conformation. We assessed ADAMTS13 conformation in remission (ADAMTS13 activity &amp;gt;60%), focusing on peak ADAMTS13 activity levels and longitudinal assessment in 420 samples across 157 patients. Fewer cases had an open conformation at peak ADAMTS13 activity than unselected remission samples with ADAMTS13 activity &amp;gt;60% (23% vs 43%). Patients with a closed ADAMTS13 conformation at peak ADAMTS13 activity had an eightfold lower relapse rate in the subsequent year (9% vs 46%) and a fivefold lower relapse rate within 2 years (23% vs 62%) compared with cases with an open conformation. Patients with an open conformation at peak ADAMTS13 activity required preemptive anti-CD20 treatment earlier than those with a closed conformation (median, 10 vs 25 months). Longitudinally, an open conformation was evident at, and often preceded relapse. When the conformation was already open before relapse, an increase in the conformation index at relapse was seen despite the undetectable anti-ADAMTS13 immunoglobulin G (IgG) antibody. In cases with detectable anti-ADAMTS13 IgG antibody, these became undetectable before achieving a closed conformation, highlighting the relapse risk even with undetectable anti-ADAMTS13 IgG antibody and the clinical utility of open\/closed during monitoring. To our knowledge, this is the first study to show an association between relapse risk and ADAMTS13 conformation when activity levels are at a peak. The open conformation identifies antibody-mediated subclinical disease that is not detectable by the current ADAMTS13 testing.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1182\/blood.2023023269","type":"journal-article","created":{"date-parts":[[2024,3,19]],"date-time":"2024-03-19T14:55:00Z","timestamp":1710860100000},"page":"2644-2653","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":21,"title":["Peak ADAMTS13 activity to assess ADAMTS13 conformation and risk of relapse in immune-mediated thrombotic thrombocytopenic purpura"],"prefix":"10.1182","volume":"143","author":[{"ORCID":"https:\/\/orcid.org\/0009-0007-6177-7162","authenticated-orcid":false,"given":"Nithya","family":"Prasannan","sequence":"first","affiliation":[{"name":"1Department of Haematology, University College London Hospitals NHS Foundation Trust, London, United Kingdom"},{"name":"2Haemostasis Research Unit, Institute of Cardiovascular Science, University College London, London, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bertina","family":"Dragunaite","sequence":"additional","affiliation":[{"name":"2Haemostasis Research Unit, Institute of Cardiovascular Science, University College London, London, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maryam","family":"Subhan","sequence":"additional","affiliation":[{"name":"2Haemostasis Research Unit, Institute of Cardiovascular Science, University College London, London, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mari","family":"Thomas","sequence":"additional","affiliation":[{"name":"1Department of Haematology, University College London Hospitals NHS Foundation Trust, London, United Kingdom"},{"name":"2Haemostasis Research Unit, Institute of Cardiovascular Science, University College London, London, United Kingdom"},{"name":"3National Institute for Health Research Cardiometabolic Programme, Cardiovascular BRC, University College London Hospital\/University College London, London, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1044-9499","authenticated-orcid":false,"given":"Rens","family":"de Groot","sequence":"additional","affiliation":[{"name":"2Haemostasis Research Unit, Institute of Cardiovascular Science, University College London, London, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Deepak","family":"Singh","sequence":"additional","affiliation":[{"name":"4Special Coagulation, Health Services Laboratories, London, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2288-8277","authenticated-orcid":false,"given":"Karen","family":"Vanhoorelbeke","sequence":"additional","affiliation":[{"name":"5Laboratory for Thrombosis Research, Interdisciplinary Research Facility Life Sciences, Katholieke Universiteit Leuven Campus Kulak Kortrijk, Kortrijk, Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marie","family":"Scully","sequence":"additional","affiliation":[{"name":"1Department of Haematology, University College London Hospitals NHS Foundation Trust, London, United Kingdom"},{"name":"2Haemostasis Research Unit, Institute of Cardiovascular Science, University College London, London, United Kingdom"},{"name":"3National Institute for Health Research Cardiometabolic Programme, Cardiovascular BRC, University College London Hospital\/University College London, London, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","reference":[{"issue":"3","key":"2024062015210689900_bib1","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1111\/j.1365-2141.2012.09167.x","article-title":"Guidelines on the diagnosis and management of thrombotic thrombocytopenic purpura and other thrombotic microangiopathies","volume":"158","author":"Scully","year":"2012","journal-title":"Br J Haematol"},{"issue":"2","key":"2024062015210689900_bib2","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1111\/jth.13571","article-title":"Consensus on the standardization of terminology in thrombotic thrombocytopenic purpura and related thrombotic microangiopathies","volume":"15","author":"Scully","year":"2017","journal-title":"J\u00a0Thromb Haemost"},{"issue":"3","key":"2024062015210689900_bib3","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1182\/blood.V50.3.413.413","article-title":"Plasmapheresis in the treatment of thrombotic thrombocytopenic purpura","volume":"50","author":"Bukowski","year":"1977","journal-title":"Blood"},{"issue":"3","key":"2024062015210689900_bib4","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1111\/jth.12114","article-title":"Rituximab for thrombotic thrombocytopenic purpura: benefit of early administration during acute episodes and use of prophylaxis to prevent relapse","volume":"11","author":"Westwood","year":"2013","journal-title":"J\u00a0Thromb Haemost"},{"issue":"6","key":"2024062015210689900_bib5","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1056\/NEJMoa1505533","article-title":"For the TI. caplacizumab for acquired\u00a0thrombotic thrombocytopenic purpura","volume":"374","author":"Peyvandi","year":"2016","journal-title":"N\u00a0Engl J Med"},{"issue":"4","key":"2024062015210689900_bib6","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1056\/NEJMoa1806311","article-title":"Caplacizumab treatment for acquired thrombotic thrombocytopenic purpura","volume":"380","author":"Scully","year":"2019","journal-title":"N\u00a0Engl J Med"},{"issue":"1","key":"2024062015210689900_bib7","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1111\/j.1365-2141.2005.05420.x","article-title":"FRETS-VWF73, a first fluorogenic substrate for ADAMTS13 assay","volume":"129","author":"Kokame","year":"2005","journal-title":"Br J Haematol"},{"issue":"1","key":"2024062015210689900_bib8","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1002\/rth2.12461","article-title":"Diagnosis and follow-up of thrombotic thrombocytopenic purpura with an automated chemiluminescent ADAMTS13 activity immunoassay","volume":"5","author":"Beranger","year":"2021","journal-title":"Res Pract Thromb Haemost"},{"issue":"3","key":"2024062015210689900_bib9","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1182\/blood.2022017023","article-title":"Long-term risk of relapse in immune-mediated thrombotic thrombocytopenic purpura and the role of anti-CD20 therapy","volume":"141","author":"Doyle","year":"2023","journal-title":"Blood"},{"issue":"21","key":"2024062015210689900_bib10","doi-asserted-by":"crossref","first-page":"4480","DOI":"10.1182\/bloodadvances.2021004971","article-title":"Anti-cysteine\/spacer antibodies that open ADAMTS13 are a common feature in iTTP","volume":"5","author":"De Waele","year":"2021","journal-title":"Blood Adv"},{"issue":"52","key":"2024062015210689900_bib11","doi-asserted-by":"crossref","first-page":"18578","DOI":"10.1073\/pnas.1411979112","article-title":"Conformational activation of ADAMTS13","volume":"111","author":"South","year":"2014","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"2","key":"2024062015210689900_bib12","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1111\/jth.13922","article-title":"An open conformation of ADAMTS-13 is a hallmark of acute acquired thrombotic thrombocytopenic purpura","volume":"16","author":"Roose","year":"2018","journal-title":"J\u00a0Thromb Haemost"},{"issue":"3","key":"2024062015210689900_bib13","first-page":"353","article-title":"Open ADAMTS13, induced by antibodies, is a biomarker for subclinical immune-mediated thrombotic thrombocytopenic purpura","volume":"136","author":"Roose","year":"2020","journal-title":"Blood"},{"issue":"18","key":"2024062015210689900_bib14","first-page":"2206","article-title":"Delayed normalization of ADAMTS13 activity in acute thrombotic thrombocytopenic purpura in the caplacizumab era","volume":"141","author":"Prasannan","year":"2023","journal-title":"Blood"},{"issue":"4","key":"2024062015210689900_bib15","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1182\/blood-2016-12-758656","article-title":"Presenting ADAMTS13 antibody and\u00a0antigen levels predict prognosis in immune-mediated\u00a0thrombotic thrombocytopenic purpura","volume":"130","author":"Alwan","year":"2017","journal-title":"Blood"},{"issue":"3","key":"2024062015210689900_bib16","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1111\/j.1365-2141.2006.06448.x","article-title":"Remission in acute refractory and relapsing\u00a0thrombotic thrombocytopenic purpura following rituximab is associated with a reduction in IgG antibodies to ADAMTS-13","volume":"136","author":"Scully","year":"2007","journal-title":"Br J Haematol"},{"issue":"5","key":"2024062015210689900_bib17","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1097\/MOH.0000000000000602","article-title":"Insights into ADAMTS13 structure: impact on thrombotic thrombocytopenic purpura diagnosis and management","volume":"27","author":"Roose","year":"2020","journal-title":"Curr Opin Hematol"},{"issue":"4","key":"2024062015210689900_bib18","doi-asserted-by":"crossref","first-page":"101132","DOI":"10.1016\/j.jbc.2021.101132","article-title":"Conformational plasticity of ADAMTS13 in hemostasis and autoimmunity","volume":"297","author":"Ercig","year":"2021","journal-title":"J\u00a0Biol Chem"},{"issue":"17","key":"2024062015210689900_bib19","doi-asserted-by":"crossref","first-page":"1899","DOI":"10.1182\/blood-2018-11-886275","article-title":"Phylogenetic and functional analysis of ADAMTS13 identifies highly conserved domains essential for allosteric regulation","volume":"133","author":"Muia","year":"2019","journal-title":"Blood"},{"issue":"12","key":"2024062015210689900_bib20","doi-asserted-by":"crossref","first-page":"2722","DOI":"10.1111\/jth.15873","article-title":"Mechanisms of ADAMTS13 regulation","volume":"20","author":"DeYoung","year":"2022","journal-title":"J\u00a0Thromb Haemost"},{"issue":"1","key":"2024062015210689900_bib21","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1182\/bloodadvances.2022008885","article-title":"ADAMTS13 conformation and immunoprofiles in Japanese patients with immune-mediated thrombotic thrombocytopenic purpura","volume":"7","author":"Sakai","year":"2023","journal-title":"Blood Adv"},{"issue":"2","key":"2024062015210689900_bib22","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1111\/bjh.18192","article-title":"The use of Obinutuzumab and ofatumumab in the treatment of immune thrombotic thrombocytopenic purpura","volume":"198","author":"Doyle","year":"2022","journal-title":"Br J Haematol"},{"issue":"2","key":"2024062015210689900_bib23","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1016\/j.jtha.2023.10.014","article-title":"Open ADAMTS13 conformation index predicts earlier relapse in immune-mediated thrombotic thrombocytopenic purpura","volume":"22","author":"De Waele","year":"2024","journal-title":"J\u00a0Thromb Haemost"},{"issue":"9","key":"2024062015210689900_bib24","doi-asserted-by":"crossref","first-page":"903","DOI":"10.1182\/blood-2018-02-791533","article-title":"The role of ADAMTS13 testing in the diagnosis and management of thrombotic microangiopathies and thrombosis","volume":"132","author":"Masias","year":"2018","journal-title":"Blood"}],"container-title":["Blood"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ashpublications.org\/blood\/article-pdf\/doi\/10.1182\/blood.2023023269\/2230220\/blood_bld-2023-023269-main.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/ashpublications.org\/blood\/article-pdf\/doi\/10.1182\/blood.2023023269\/2230220\/blood_bld-2023-023269-main.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,6,20]],"date-time":"2024-06-20T11:21:30Z","timestamp":1718882490000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/blood\/article\/143\/25\/2644\/515348\/Peak-ADAMTS13-activity-to-assess-ADAMTS13"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,6,20]]},"references-count":24,"journal-issue":{"issue":"25","published-print":{"date-parts":[[2024,6,20]]}},"URL":"https:\/\/doi.org\/10.1182\/blood.2023023269","relation":{},"ISSN":["0006-4971","1528-0020"],"issn-type":[{"value":"0006-4971","type":"print"},{"value":"1528-0020","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,6,20]]}}}